Drug Approval | October 16, 2024
Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic NSCLC
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
The acquisition will strengthen the overall company’s position as leading global CRO services partner
he company will focus on production of any pharmaceutical and biotechnological products
Subscribe To Our Newsletter & Stay Updated
